metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
mGC or mGEJC - L1 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - PDL1 positive
versus placebo plus SoC
	pembrolizumab alone
	KEYNOTE-062 (P vs C ; CPS>10), 2020 JAMA Oncol 2020 Sep 3;6(10):1-10. Journal of Clinical Oncology NCT02494583	RCT	mGC or mGEJC - L1 - PDL1 positive	pembrolizumab	placebo plus chemotherapy (cisplatin plus fluorouracil or capecitabine)	first-line treatment for participants with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma (PDL1 CPS>10)	92 / 90	some concern	suggested	suggested 31 % decrease in deaths (OS) (PE)
versus Standard of Care (SoC)
	pembrolizumab alone
	KEYNOTE-062 (P vs C ; CPS>1), 2020 JAMA Oncol 2020 Sep 3;6(10):1-10. Journal of Clinical Oncology NCT02494583	RCT	mGC or mGEJC - L1 - PDL1 positive	pembrolizumab	placebo plus chemotherapy (5FU or capecitabine plus cisplatin)	first-line treatment for participants with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma	256 / 250	some concern	inconclusive	statistically significant 66 % increase in progression or deaths (PFS) statistically significant 71 % decrease in objective responses (ORR)
mGC or mGEJC - L2 - all population metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - all population
versus paclitaxel
	pembrolizumab alone
	KEYNOTE-061 (all population), 2018 Lancet 2018; 392:123-133 NCT02370498	RCT	mGC or mGEJC - L2 - all population	pembrolizumab	paclitaxel	patients with advanced gastric or gastro-oesophageal junction cancer that progressed on first-line chemotherapy with a platinum and fluoropyrimidine	296 / 296	some concern	inconclusive	statistically significant 49 % increase in progression or deaths (PFS)
mGC or mGEJC - L2 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - PDL1 positive
versus paclitaxel
	pembrolizumab alone
	KEYNOTE-061 (PDL1 CPS>1), 2018 Lancet 2018; 392:123-133 Gastric Cancer 2022; 25:197-206-. NCT02370498	RCT	mGC or mGEJC - L2 - PDL1 positive	pembrolizumab	paclitaxel	patients with advanced gastric or gastro-oesophageal junction cancer that progressed on first-line chemotherapy with a platinum and fluoropyrimidine (PDL1 CPS>1 population)	196 / 199	some concern	inconclusive	inconclusive 18 % decrease in deaths (OS) (PE) statistically significant 27 % increase in progression or deaths (PFS) (PE)

mGC or mGEJC - L1 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - PDL1 positive

mGC or mGEJC - L2 - all population metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - all population

mGC or mGEJC - L2 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 2nd Line (L2) mGC or mGEJC - L2 - PDL1 positive